

Supplementary table 2. Patient characteristics.

Characteristics		Total	%	
Patients, n		32	100	
Sex	Male	18	56	
	Female	14	44	
Age in years, median (range)	Median	67.5 (47-80)		
Treatment	Radiation+Nivolumab+Ipilimumab	17	53	
	Radiation+Nivolumab	15	47	
Best obtained clinical response				
	PR	7	22	
	SD	14	44	
	PD	11	34	
PFS status at last follow up	Progression	31	97	
	No progression	1	3	
Survival status at last follow up	Deceased	30	94	
	Alive	2	6	
Follow up days, median (range)		219 (65-1511)		
Histology	Pancreatic ductal adenocarcinoma	29	91	
	Unspecified	3	9	
CA199, median (range)		709 (3-10000)		
CRP, median (range)		13.5 (3-170)		
Bilirubin, median (range)		9 (5-47)		
Absolute neutrophil count, median (range)		5 (1.2-14.5)		
Albumin, median (range)		41 (32-49)		
Lymphocyte count, median (range)		1.45 (0.9-2.5)		
NLR, median (range)	High	10	31	
	Low	22	69	
mGPS		0	13	41
		1	18	56
		2	1	3
Best obtained response to last the	PR	6	19	
	SD	11	34	
	PD	15	47	
Prior lines of therapy		1	13	41
		2	13	41
		3	5	16
		4	1	3